Guerbet

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Approved2

Phase 31

Phase 22

Phase 12

Preclinical4

By Therapeutic Area

top 5

Oncology

440%

Cardiovascular

220%

Neurology

220%

Nephrology

110%

Respiratory

110%

R&D Momentum

30/100

Pipeline Velocity

6/100

Trial Completion Rate

88/100

Pipeline Concentration

26/100

Pipeline Freshness

71/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 26, 2026TrialEfficacy and Safety of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children

Feb 2, 2026TrialEvaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

Sep 7, 2023TrialPerformance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

Sep 21, 2022FDAElucirem — ELUCIREM

Sep 21, 2022TrialGadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

May 10, 2021TrialPharmacokinetics and Safety of Gadopiclenol in Japanese Healthy Volunteers

Mar 24, 2021TrialEffect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Aug 27, 2019TrialEfficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

4 more events

Jun 3, 2019TrialEfficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Nov 6, 2018TrialPharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI

Nov 29, 2017TrialA Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures

Oct 13, 2017TrialPharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

EluciremSep 19, 2028 EluciremAug 6, 2039 Elucirem2 patentsJan 17, 2040

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

DotaremApproved

Vascular Disease

DotaremPhase 3

Nephrology

Renal Insufficiency

OmniscanApproved

Neurology

Multiple Sclerosis

MultihancePreclinical

ProhancePreclinical

Oncology

Breast Cancer

MultihancePhase 2

DotaremPreclinical

Glioblastoma

ProhancePreclinical

Glioma

ProhancePhase 1

Hepatocellular Carcinoma

EovistPreclinical

Liver Cancer

EovistPhase 1

MultihancePreclinical

Prostate Cancer

MultihancePhase 2

Respiratory

Pulmonary Fibrosis

DotaremPhase 2

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Lipiodol — LIPIODOL

Application NDA009190 (NDA)

20171 event

FDAMar 31

Dotarem — DOTAREM

Application NDA204781 (NDA)

20221 event

FDASep 21

Elucirem — ELUCIREM

Application NDA216986 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)